A Phase 2 interventional study of CDP6038 (olokizumab) in Rheumatoid Arthritis, sponsored by UCB BIOSCIENCES, Inc.. Terminated at 32 sites in 3 countries. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2022-05-20.
Sponsored by UCB BIOSCIENCES, Inc. (part of UCB S.A.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing olokizumab in Arthritis, Rheumatoid — none open to participants now, none under way, none of them phase 3. olokizumab · Arthritis, Rheumatoid.
Among the 10 studies testing olokizumab in Arthritis, Rheumatoid, this one is the 8th largest by enrollment, is the only one that started in 2012, is one of 4 in phase 2, and was the 5th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.
Browse Arthritis, Rheumatoid studies →None of the 10 studies testing olokizumab in Arthritis, Rheumatoid is open now. The open studies under Arthritis, Rheumatoid, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 5 · Phase 3 4
First in 2009; this study’s year is marked. 1 started in 2012.
This study's enrollment of 103 is close to the median of 95 across 2,221 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 206 across the 10 interventional studies. Of the 10 that completed or were terminated, 7 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 10 have an industry lead sponsor. The 4 most frequent:
This study is registered under UCB BIOSCIENCES, Inc., one of the names counted as UCB S.A.. Under that name alone:
UCB BIOSCIENCES, Inc. is the lead sponsor of 29 studies on the registry; 2 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.
42 studies in Arthritis, Rheumatoid by UCB S.A.: 1 open now, 2 under way, none of them phase 3. Of 39 finished, 26 (67%) have results posted.
Among the 42 studies in Arthritis, Rheumatoid by UCB S.A., this one is the 26th largest by enrollment of the 34 interventional ones that give a count, is one of 5 that started in 2012, is one of 5 in phase 2, and was the 29th registered.
UCB S.A.’s Arthritis, Rheumatoid studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing olokizumab in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among UCB S.A.’s 42 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the long-term safety and tolerability of CDP6038 (olokizumab) treatment in adult subjects with active rheumatoid arthritis (RA) who completed study RA0083 [NCT01463059].
Male and female subjects were randomized in a multi-center, open-label, follow-up study to assess the long-term safety and efficacy of a subcutaneous dose of 120 mg CDP6038 (olokizumab), every 2 weeks (q2w), for the treatment of active RA.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CDP6038 (olokizumab) 120 mg: subcutaneous injections at q2w (every two weeks). RA0089 is a single arm study, however, analysis will be presented according to the original treatment arms of the parent study NCT01463059 (RA0083).
Biological: CDP6038 (olokizumab)
Biological/Vaccine: CDP6038 (olokizumab) 100 mg/mL solution for subcutaneous (sc) injection
Total Number of Subjects With Treatment-emergent Adverse Events (TEAEs)
Reported TEAEs included adverse events that started or worsened after the first dose of CDP6038 (olokizumab) in Study RA0089 and within 30 days after the last dose.
Time frame: From Baseline (Week 0 of Study RA0089) until 30 days after the last dose (maximum up to 562 days)
Change From Baseline (Week 0 of Study RA0083) in the Disease Activity Score-28-joint Count (C-reactive Protein) (DAS28[CRP]) at Week 12 of Study RA0089
DAS28(CRP) was calculated using tender/painful joint count (TJC) and swollen joint count (SJC) from 28 joints, Patient's Global Assessment of Disease Activity (PtGADA)-Visual Analog Scale (VAS), and CRP as per formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: •TJC and SJC: assessed on same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. 28 joints included shoulders, elbows, wrists; metacarpophalangeal (MCP), thumb interphalangeal (IP), and proximal interphalangeal (PIP) joints of hands; and knees. Scores on DAS28(CRP) range from 0 to approximately 10, where scores greater than (\>) 5.1 correspond with active disease, scores less than (\<) 3.2 correspond with well controlled disease, and scores \<2.6 correspond with remission or similar. A negative change in DAS28(CRP) score indicates an improvement in disease activity.
Time frame: Baseline (Week 0 of Study RA0083) and Week 12 (Study RA0089)
Change From Baseline (Week 0 of Study RA0083) in DAS28(CRP) at Week 24 of Study RA0089
DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, andCRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included shoulders, elbows, wrists; MCP, thumb IP, and PIP joints of hands; and knees. Scores on DAS28(CRP) range from 0 to approximately 10, where scores \>5.1 correspond with active disease, scores \<3.2 correspond with well controlled disease, and scores \<2.6 correspond with remission or similar. A negative change in DAS28(CRP) score indicates an improvement in disease activity.
Time frame: Baseline (Week 0 of Study RA0083) and Week 24 (Study RA0089)
Change From Baseline (Week 0 of Study RA0083) in DAS28(CRP) at Week 48 of Study RA0089
DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, andCRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included shoulders, elbows, wrists; MCP, thumb IP, and PIP joints of hands; and knees. Scores on DAS28(CRP) range from 0 to approximately 10, where scores \>5.1 correspond with active disease, scores \<3.2 correspond with well controlled disease, and scores \<2.6 correspond with remission or similar. A negative change in DAS28(CRP) score indicates an improvement in disease activity.
Time frame: Baseline (Week 0 of Study RA0083) and Week 48 (Study RA0089)
Change From Baseline (Week 0 of Study RA0083) in DAS28(CRP) at Week 96 of Study RA0089
DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, andCRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included shoulders, elbows, wrists; MCP, thumb IP, and PIP joints of hands; and knees. Scores on DAS28(CRP) range from 0 to approximately 10, where scores \>5.1 correspond with active disease, scores \<3.2 correspond with well controlled disease, and scores \<2.6 correspond with remission or similar. A negative change in DAS28(CRP) score indicates an improvement in disease activity. Since the study was terminated early before Week 96, no results data are available for analysis at the Week 96 time point and this Outcome Measure has zero total participants analyzed.
Time frame: Baseline (Week 0 of Study RA0083) and Week 96 (Study RA0089)
The American College of Rheumatology (ACR) 20% (ACR20) Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0083) at Week 12 of Study RA0089
ACR20 represents at least 20% improvement from Baseline in TJC (68 joints) + in SJC (66 joints) + in at least 3 of 5 core set measures: PtGADA-VAS, Physician's Global Assessment of Disease Activity (PhGADA)-VAS, Patient's Assessment of Arthritis Pain (PAAP)-VAS, Health Assessment Questionnaire-Disability Index (HAQ-DI) and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), total score (0-3) computed from item scores, with lower scores meaning less disability. • CRP in mg/L. Missing values were considered as non-responding status.
Time frame: Baseline (Week 0 of Study RA0083) and Week 12 (Study RA0089)
The ACR20 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0083) at Week 24 of Study RA0089
ACR20 represents at least 20% improvement from Baseline in TJC (68 joints) + SJC (66 joints) + in at least 3 of 5 core set measures: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), total score (0-3) computed from item scores, with lower scores meaning less disability. • CRP in mg/L. Missing values were considered as non-responding status.
Time frame: Baseline (Week 0 of Study RA0083) and Week 24 (Study RA0089)
The ACR20 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0083) at Week 48 of Study RA0089
ACR20 represents at least 20% improvement from Baseline in TJC (68 joints) + SJC (66 joints) + in at least 3 of 5 core set measures: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), total score (0-3) computed from item scores, with lower scores meaning less disability. • CRP in mg/L. Missing values were considered as non-responding status.
Time frame: Baseline (Week 0 of Study RA0083) and Week 48 (Study RA0089)
The ACR20 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0083) at Week 96 of Study RA0089
ACR20: at least 20% improvement from Baseline in TJC (68 joints) + SJC (66 joints) + in at least 3 of 5 core set measures: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), total score (0-3) computed from item scores, with lower scores meaning less disability. • CRP in mg/L. Missing values were considered as non-responding status. Since the study was terminated early before Week 96, no data was collected and analyzed at the Week 96 and this Outcome Measure has zero total participants analyzed.
Time frame: Baseline (Week 0 of Study RA0083) and Week 96 (Study RA0089)
The ACR 50% (ACR50) Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0083) at Week 12 of Study RA0089
ACR50 represents at least 50% improvement from Baseline in TJC (68 joints) + in SJC (66 joints) + in at least 3 of 5 core set measures: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), total score (0-3) computed from item scores, with lower scores meaning less disability. • CRP in mg/L. Missing values were considered as non-responding status.
Time frame: Baseline (Week 0 of Study RA0083) and Week 12 (Study RA0089)
The ACR50 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0083) at Week 24 of Study RA0089
ACR50 represents at least 50% improvement from Baseline in TJC (68 joints) + in SJC (66 joints) + in at least 3 of 5 core set measures: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), total score (0-3) computed from item scores, with lower scores meaning less disability. • CRP in mg/L. Missing values were considered as non-responding status.
Time frame: Baseline (Week 0 of Study RA0083) and Week 24 (Study RA0089)
The ACR50 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0083) at Week 48 of Study RA0089
ACR50 represents at least 50% improvement from Baseline in TJC (68 joints) + in SJC (66 joints) + in at least 3 of 5 core set measures: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), total score (0-3) computed from item scores, with lower scores meaning less disability. • CRP in mg/L. Missing values were considered as non-responding status.
Time frame: Baseline (Week 0 of Study RA0083) and Week 48 (Study RA0089)
The ACR50 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0083) at Week 96 of Study RA0089
ACR50:atleast 50% improvement from Baseline in TJC (68 joints) + in SJC (66 joints) + in at least 3 of 5 core set measures: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), total score (0-3) computed from item scores, with lower scores meaning less disability. • CRP in mg/L. Missing values were considered as non-responding status. Since the study was terminated early before Week 96, no data was collected and analyzed at the Week 96 and this Outcome Measure has zero total participants analyzed.
Time frame: Baseline (Week 0 of Study RA0083) and Week 96 (Study RA0089)
The ACR 70% (ACR70) Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0083) at Week 12 of Study RA0089
ACR70 represents at least 70% improvement from Baseline in TJC (68 joints) + in SJC (66 joints) + in at least 3 of 5 core set measures: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), total score (0-3) computed from item scores, with lower scores meaning less disability. • CRP in mg/L. Missing values were considered as non-responding status.
Time frame: Baseline (Week 0 of Study RA0083) and Week 12 (Study RA0089)
The ACR70 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0083) at Week 24 of Study RA0089
ACR70 represents at least 70% improvement from Baseline in TJC (68 joints) + in SJC (66 joints) + in at least 3 of 5 core set measures: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), total score (0-3) computed from item scores, with lower scores meaning less disability. • CRP in mg/L. Missing values were considered as non-responding status.
Time frame: Baseline (Week 0 of Study RA0083) and Week 24 (Study RA0089)
The ACR70 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0083) at Week 48 of Study RA0089
ACR70 represents at least 70% improvement from Baseline in TJC (68 joints) + in SJC (66 joints) + in at least 3 of 5 core set measures: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), total score (0-3) computed from item scores, with lower scores meaning less disability. • CRP in mg/L. Missing values were considered as non-responding status.
Time frame: Baseline (Week 0 of Study RA0083) and Week 48 (Study RA0089)
The ACR70 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0083) at Week 96 of Study RA0089
ACR70:atleast 70% improvement from Baseline in TJC (68 joints) + in SJC (66 joints) + in at least 3 of 5 core set measures: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), total score (0-3) computed from item scores, with lower scores meaning less disability. • CRP in mg/L. Missing values were considered as non-responding status. Since the study was terminated early before Week 96, no data was collected and analyzed at the Week 96 and this Outcome Measure has zero total participants analyzed.
Time frame: Baseline (Week 0 of Study RA0083) and Week 96 (Study RA0089)
Percentage of Subjects With DAS28(CRP) <2.6 at Week 12 of Study RA0089
DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, andCRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included shoulders, elbows, wrists; MCP, thumb IP, and PIP joints of hands; and knees. Scores on DAS28(CRP) range from 0 to approximately 10, where scores \>5.1 correspond with active disease, scores \<3.2 correspond with well controlled disease, and scores \<2.6 correspond with remission or similar. Percentage of participants with DAS28(CRP) \<2.6 were reported.
Time frame: Week 12 (Study RA0089)
Percentage of Subjects With DAS28(CRP) <2.6 at Week 24 of Study RA0089
DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, andCRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included shoulders, elbows, wrists; MCP, thumb IP, and PIP joints of hands; and knees. Scores on DAS28(CRP) range from 0 to approximately 10, where scores \>5.1 correspond with active disease, scores \<3.2 correspond with well controlled disease, and scores \<2.6 correspond with remission or similar. Percentage of participants with DAS28(CRP) \<2.6 were reported.
Time frame: Week 24 (Study RA0089)
Percentage of Subjects With DAS28(CRP) <2.6 at Week 48 of Study RA0089
DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, andCRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included shoulders, elbows, wrists; MCP, thumb IP, and PIP joints of hands; and knees. Scores on DAS28(CRP) range from 0 to approximately 10, where scores \>5.1 correspond with active disease, scores \<3.2 correspond with well controlled disease, and scores \<2.6 correspond with remission or similar. Percentage of participants with DAS28(CRP) \<2.6 were reported.
Time frame: Week 48 (Study RA0089)
Percentage of Subjects With DAS28(CRP) <2.6 at Week 96 of Study RA0089
DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, andCRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included shoulders, elbows, wrists; MCP, thumb IP, and PIP joints of hands; and knees. Scores on DAS28(CRP) range from 0 to approximately 10, where scores \>5.1 correspond with active disease, scores \<3.2 correspond with well controlled disease, and scores \<2.6 correspond with remission or similar. Percentage of participants with DAS28(CRP) \<2.6 were reported. Since the study was terminated early before Week 96, no data was collected and analyzed at the Week 96 and this Outcome Measure has zero total participants analyzed.
Time frame: Week 96 (Study RA0089)
Percentage of Subjects With DAS28(CRP) ≤3.2 at Week 12 of Study RA0089
DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, andCRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included shoulders, elbows, wrists; MCP, thumb IP, and PIP joints of hands; and knees. Scores on DAS28(CRP) range from 0 to approximately 10, where scores \>5.1 correspond with active disease, scores \<3.2 correspond with well controlled disease, and scores \<2.6 correspond with remission or similar. Percentage of participants with DAS28(CRP) less than or equal to (≤) 3.2 were reported.
Time frame: Week 12 (Study RA0089)
Percentage of Subjects With DAS28(CRP) ≤3.2 at Week 24 of Study RA0089
DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, andCRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included shoulders, elbows, wrists; MCP, thumb IP, and PIP joints of hands; and knees. Scores on DAS28(CRP) range from 0 to approximately 10, where scores \>5.1 correspond with active disease, scores \<3.2 correspond with well controlled disease, and scores \<2.6 correspond with remission or similar. Percentage of participants with DAS28(CRP) ≤3.2 were reported.
Time frame: Week 24 (Study RA0089)
Percentage of Subjects With DAS28(CRP) ≤3.2 at Week 48 of Study RA0089
DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, andCRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included shoulders, elbows, wrists; MCP, thumb IP, and PIP joints of hands; and knees. Scores on DAS28(CRP) range from 0 to approximately 10, where scores \>5.1 correspond with active disease, scores \<3.2 correspond with well controlled disease, and scores \<2.6 correspond with remission or similar. Percentage of participants with DAS28(CRP) ≤3.2 were reported.
Time frame: Week 48 (Study RA0089)
Percentage of Subjects With DAS28(CRP) ≤3.2 at Week 96 of Study RA0089
DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, andCRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included shoulders, elbows, wrists; MCP, thumb IP, and PIP joints of hands; and knees. Scores on DAS28(CRP) range from 0 to approximately 10, where scores \>5.1 correspond with active disease, scores \<3.2 correspond with well controlled disease, and scores \<2.6 correspond with remission or similar. Since the study was terminated early before Week 96, no data was collected and analyzed at the Week 96 and this Outcome Measure has zero total participants analyzed.
Time frame: Week 96 (Study RA0089)
Change From Baseline (Week 0 of Study RA0083) in the Clinical Disease Activity Index (CDAI) at Week 48 of Study RA0089
CDAI was calculated using the TJC (28 joints), SJC (28 joints), PtGADA-VAS and PhGADA-VAS, according to the following formula: SJC + TJC + PtGADA + PhGADA Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 10 cm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • PhGADA: 10 cm VAS (0=very good, asymptomatic and no limitation of normal activities; 100=very poor, very severe symptoms which were intolerable and inability to carry out all normal activities). The 28 joints included the shoulders, elbows, wrists; MCP, thumb IP, and PIP joints of the hands; and the knees. Total score range is from 0-100, with the high scores representing high disease activity. A negative change in CDAI score indicates an improvement in disease activity.
Time frame: Baseline (Week 0 of Study RA0083) and Week 48 (Study RA0089)
Change From Baseline (Week 0 of Study RA0083) CDAI at Week 96 of Study RA0089
CDAI was calculated using the TJC (28 joints), SJC (28 joints), PtGADA-VAS and PhGADA-VAS, according to the following formula: SJC + TJC + PtGADA + PhGADA Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 10 cm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • PhGADA: 10 cm VAS (0=very good, asymptomatic and no limitation of normal activities; 100=very poor, very severe symptoms which were intolerable and inability to carry out all normal activities). The 28 joints included the shoulders, elbows, wrists; MCP, thumb IP, and PIP joints of the hands; and the knees. Total score range is from 0-100, with the high scores representing high disease activity. A negative change in CDAI score indicates an improvement in disease activity. Since the study was terminated early before Week 96, no data was collected and analyzed at the Week 96 and this Outcome Measure has zero total participants analyzed.
Time frame: Baseline (Week 0 of Study RA0083) and Week 96 (Study RA0089)
Change From Baseline (Week 0 of Study RA0083) in the Simplified Disease Activity Index (SDAI) at Week 48 of Study RA0089
SDAI was calculated using the TJC (28 joints), SJC (28 joints), PtGADA-VAS, PhGADA-VAS and CRP (mg/dL\]), according to the following formula: SJC + TJC + PtGADA + PhGADA + CRP (mg/dL) Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 10 cm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • PhGADA: 10 cm VAS (0=very good, asymptomatic and no limitation of normal activities; 100=very poor, very severe symptoms which were intolerable and inability to carry out all normal activities). • CRP range was from 0 to 10 mg/dL. The 28 joints included the shoulders, elbows, wrists; MCP, thumb IP, and PIP joints of the hands; and the knees. The SDAI score ranges from 0 to 86, with higher scores representing worse disease. A negative change in SDAI score indicates an improvement in disease activity.
Time frame: Baseline (Week 0 of Study RA0083) and Week 48 (Study RA0089)
Change From Baseline (Week 0 of Study RA0083) in the SDAI at Week 96 of Study RA0089
SDAI was calculated using the TJC (28 joints), SJC (28 joints), PtGADA-VAS, PhGADA-VAS and CRP (mg/dL\]), as per formula: SJC + TJC + PtGADA + PhGADA + CRP (mg/dL) Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 10 cm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • PhGADA: 10 cm VAS (0=very good, asymptomatic and no limitation of normal activities; 100=very poor, very severe symptoms which were intolerable and inability to carry out all normal activities). • CRP range was from 0 to 10 mg/dL. The 28 joints included the shoulders, elbows, wrists; MCP, thumb IP, and PIP joints of the hands; and the knees. SDAI score ranges from 0 to 86, with higher scores representing worse disease. A negative change in SDAI score indicates an improvement in disease activity. Since the study was terminated early before Week 96, no data was collected and analyzed at the Week 96 and this Outcome Measure has zero total participants analyzed.
Time frame: Baseline (Week 0 of Study RA0083) and Week 96 (Study RA0089)
Plasma Concentration of CDP6038 (Olokizumab) at Weeks 4, 8, 12, 16, 24, 32, 40, 48, 72, 96, 120
The CDP6038 (olokizumab) plasma levels data were not collected and analyzed. This Outcome Measure therefore has zero total participants analyzed.
Time frame: Weeks 4, 8, 12, 16, 24, 32, 40, 48, 72, 96, 120
Plasma Concentration of Anti-CDP6038 (Olokizumab) Antibodies at Weeks 4, 8, 12, 16, 24, 32, 40, 48, 72, 96 and 120
The CDP6038 (olokizumab) plasma levels data were not collected and analyzed. This Outcome Measure therefore has zero total participants analyzed.
Time frame: Weeks 4, 8, 12, 16, 24, 32, 40, 48, 72, 96, 120
The present study was an open-label extension to study RA0083 (NCT01463059). Subjects completing the 12-week treatment period of study RA0083 had the opportunity to participate in this study. First subject enrolled: 26 January 2012. Last subject completed: 27 November 2013.
| Milestone | RA0083 CDP6038 (Olokizumab) 120 mg q2w | RA0083 CDP6038 (Olokizumab) 120 mg q4w | RA0083 CDP6038 (Olokizumab) 240 mg q4w | RA0083 CDP6038 (Olokizumab) 60 mg q2w | RA0083 CDP6038 (Olokizumab) 60 mg q4w | RA0083 Placebo |
|---|---|---|---|---|---|---|
| Started | 10 | 15 | 11 | 15 | 28 | 24 |
| Completed | 10 | 12 | 7 | 11 | 21 | 21 |
| Not completed | 0 | 3 | 4 | 4 | 7 | 3 |
| Withdrew: Adverse event | 0 | 1 | 2 | 2 | 2 | 1 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 1 | 1 | 0 |
| Withdrew: Exclusion criteria | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Positive for purified protein derivative | 0 | 0 | 1 | 0 | 1 | 0 |
| Withdrew: Withdrawal criteria | 0 | 0 | 1 | 0 | 3 | 1 |
| Withdrew: Ineligibility reason | 0 | 0 | 0 | 1 | 0 | 0 |
Reported TEAEs included adverse events that started or worsened after the first dose of CDP6038 (olokizumab) in Study RA0089 and within 30 days after the last dose.
| Participants | RA0083 CDP6038 (Olokizumab) 120 mg q2w | RA0083 CDP6038 (Olokizumab) 120 mg q4w | RA0083 CDP6038 (Olokizumab) 240 mg q4w | RA0083 CDP6038 (Olokizumab) 60 mg q2w | RA0083 CDP6038 (Olokizumab) 60 mg q4w | RA0083 Placebo |
|---|---|---|---|---|---|---|
| Total Number of Subjects With Treatment-emergent Adverse Events (TEAEs) | 8 | 13 | 10 | 12 | 25 | 22 |
DAS28(CRP) was calculated using tender/painful joint count (TJC) and swollen joint count (SJC) from 28 joints, Patient's Global Assessment of Disease Activity (PtGADA)-Visual Analog Scale (VAS), and CRP as per formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: •TJC and SJC: assessed on same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. 28 joints included shoulders, elbows, wrists; metacarpophalangeal (MCP), thumb interphalangeal (IP), and proximal interphalangeal (PIP) joints of hands; and knees. Scores on DAS28(CRP) range from 0 to approximately 10, where scores greater than (\>) 5.1 correspond with active disease, scores less than (\<) 3.2 correspond with well controlled disease, and scores \<2.6 correspond with remission or similar. A negative change in DAS28(CRP) score indicates an improvement in disease activity.
| units on a scale | RA0083 CDP6038 (Olokizumab) 120 mg q2w | RA0083 CDP6038 (Olokizumab) 120 mg q4w | RA0083 CDP6038 (Olokizumab) 240 mg q4w | RA0083 CDP6038 (Olokizumab) 60 mg q2w | RA0083 CDP6038 (Olokizumab) 60 mg q4w | RA0083 Placebo |
|---|---|---|---|---|---|---|
| Change From Baseline (Week 0 of Study RA0083) in the Disease Activity Score-28-joint Count (C-reactive Protein) (DAS28[CRP]) at Week 12 of Study RA0089 | -2.9618 ± 1.05692 | -2.5358 ± 1.11550 | -2.9758 ± 1.23346 | -2.7948 ± 1.28792 | -2.6837 ± 0.80614 | -2.5902 ± 1.06296 |
DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, andCRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included shoulders, elbows, wrists; MCP, thumb IP, and PIP joints of hands; and knees. Scores on DAS28(CRP) range from 0 to approximately 10, where scores \>5.1 correspond with active disease, scores \<3.2 correspond with well controlled disease, and scores \<2.6 correspond with remission or similar. A negative change in DAS28(CRP) score indicates an improvement in disease activity.
| units on a scale | RA0083 CDP6038 (Olokizumab) 120 mg q2w | RA0083 CDP6038 (Olokizumab) 120 mg q4w | RA0083 CDP6038 (Olokizumab) 240 mg q4w | RA0083 CDP6038 (Olokizumab) 60 mg q2w | RA0083 CDP6038 (Olokizumab) 60 mg q4w | RA0083 Placebo |
|---|---|---|---|---|---|---|
| Change From Baseline (Week 0 of Study RA0083) in DAS28(CRP) at Week 24 of Study RA0089 | -2.6916 ± 0.75807 | -3.3277 ± 1.05841 | -3.3523 ± 0.74516 | -2.8884 ± 1.43276 | -3.0176 ± 0.82217 | -2.8235 ± 0.99271 |
DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, andCRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included shoulders, elbows, wrists; MCP, thumb IP, and PIP joints of hands; and knees. Scores on DAS28(CRP) range from 0 to approximately 10, where scores \>5.1 correspond with active disease, scores \<3.2 correspond with well controlled disease, and scores \<2.6 correspond with remission or similar. A negative change in DAS28(CRP) score indicates an improvement in disease activity.
| units on a scale | RA0083 CDP6038 (Olokizumab) 120 mg q2w | RA0083 CDP6038 (Olokizumab) 120 mg q4w | RA0083 CDP6038 (Olokizumab) 240 mg q4w | RA0083 CDP6038 (Olokizumab) 60 mg q2w | RA0083 CDP6038 (Olokizumab) 60 mg q4w | RA0083 Placebo |
|---|---|---|---|---|---|---|
| Change From Baseline (Week 0 of Study RA0083) in DAS28(CRP) at Week 48 of Study RA0089 | -2.6243 ± 1.52735 | -3.2720 ± 0.97343 | -3.2397 ± 0.85356 | -2.9625 ± 1.16236 | -2.4750 ± 1.31771 | -3.2211 ± 0.45471 |
DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, andCRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included shoulders, elbows, wrists; MCP, thumb IP, and PIP joints of hands; and knees. Scores on DAS28(CRP) range from 0 to approximately 10, where scores \>5.1 correspond with active disease, scores \<3.2 correspond with well controlled disease, and scores \<2.6 correspond with remission or similar. A negative change in DAS28(CRP) score indicates an improvement in disease activity. Since the study was terminated early before Week 96, no results data are available for analysis at the Week 96 time point and this Outcome Measure has zero total participants analyzed.
Results for this outcome have not been posted.
ACR20 represents at least 20% improvement from Baseline in TJC (68 joints) + in SJC (66 joints) + in at least 3 of 5 core set measures: PtGADA-VAS, Physician's Global Assessment of Disease Activity (PhGADA)-VAS, Patient's Assessment of Arthritis Pain (PAAP)-VAS, Health Assessment Questionnaire-Disability Index (HAQ-DI) and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), total score (0-3) computed from item scores, with lower scores meaning less disability. • CRP in mg/L. Missing values were considered as non-responding status.
| Percentage of responders | RA0083 CDP6038 (Olokizumab) 120 mg q2w | RA0083 CDP6038 (Olokizumab) 120 mg q4w | RA0083 CDP6038 (Olokizumab) 240 mg q4w | RA0083 CDP6038 (Olokizumab) 60 mg q2w | RA0083 CDP6038 (Olokizumab) 60 mg q4w | RA0083 Placebo |
|---|---|---|---|---|---|---|
| The American College of Rheumatology (ACR) 20% (ACR20) Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0083) at Week 12 of Study RA0089 | 100.0 | 60.0 | 81.8 | 71.4 | 64.3 | 70.8 |
ACR20 represents at least 20% improvement from Baseline in TJC (68 joints) + SJC (66 joints) + in at least 3 of 5 core set measures: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), total score (0-3) computed from item scores, with lower scores meaning less disability. • CRP in mg/L. Missing values were considered as non-responding status.
| Percentage of responders | RA0083 CDP6038 (Olokizumab) 120 mg q2w | RA0083 CDP6038 (Olokizumab) 120 mg q4w | RA0083 CDP6038 (Olokizumab) 240 mg q4w | RA0083 CDP6038 (Olokizumab) 60 mg q2w | RA0083 CDP6038 (Olokizumab) 60 mg q4w | RA0083 Placebo |
|---|---|---|---|---|---|---|
| The ACR20 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0083) at Week 24 of Study RA0089 | 60.0 | 46.7 | 81.8 | 57.1 | 71.4 | 66.7 |
ACR20 represents at least 20% improvement from Baseline in TJC (68 joints) + SJC (66 joints) + in at least 3 of 5 core set measures: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), total score (0-3) computed from item scores, with lower scores meaning less disability. • CRP in mg/L. Missing values were considered as non-responding status.
| Percentage of responders | RA0083 CDP6038 (Olokizumab) 120 mg q2w | RA0083 CDP6038 (Olokizumab) 120 mg q4w | RA0083 CDP6038 (Olokizumab) 240 mg q4w | RA0083 CDP6038 (Olokizumab) 60 mg q2w | RA0083 CDP6038 (Olokizumab) 60 mg q4w | RA0083 Placebo |
|---|---|---|---|---|---|---|
| The ACR20 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0083) at Week 48 of Study RA0089 | 20.0 | 13.3 | 54.5 | 21.4 | 21.4 | 33.3 |
ACR20: at least 20% improvement from Baseline in TJC (68 joints) + SJC (66 joints) + in at least 3 of 5 core set measures: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), total score (0-3) computed from item scores, with lower scores meaning less disability. • CRP in mg/L. Missing values were considered as non-responding status. Since the study was terminated early before Week 96, no data was collected and analyzed at the Week 96 and this Outcome Measure has zero total participants analyzed.
Results for this outcome have not been posted.
ACR50 represents at least 50% improvement from Baseline in TJC (68 joints) + in SJC (66 joints) + in at least 3 of 5 core set measures: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), total score (0-3) computed from item scores, with lower scores meaning less disability. • CRP in mg/L. Missing values were considered as non-responding status.
| Percentage of responders | RA0083 CDP6038 (Olokizumab) 120 mg q2w | RA0083 CDP6038 (Olokizumab) 120 mg q4w | RA0083 CDP6038 (Olokizumab) 240 mg q4w | RA0083 CDP6038 (Olokizumab) 60 mg q2w | RA0083 CDP6038 (Olokizumab) 60 mg q4w | RA0083 Placebo |
|---|---|---|---|---|---|---|
| The ACR 50% (ACR50) Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0083) at Week 12 of Study RA0089 | 70.0 | 40.0 | 54.5 | 42.9 | 42.9 | 50.0 |
ACR50 represents at least 50% improvement from Baseline in TJC (68 joints) + in SJC (66 joints) + in at least 3 of 5 core set measures: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), total score (0-3) computed from item scores, with lower scores meaning less disability. • CRP in mg/L. Missing values were considered as non-responding status.
| Percentage of responders | RA0083 CDP6038 (Olokizumab) 120 mg q2w | RA0083 CDP6038 (Olokizumab) 120 mg q4w | RA0083 CDP6038 (Olokizumab) 240 mg q4w | RA0083 CDP6038 (Olokizumab) 60 mg q2w | RA0083 CDP6038 (Olokizumab) 60 mg q4w | RA0083 Placebo |
|---|---|---|---|---|---|---|
| The ACR50 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0083) at Week 24 of Study RA0089 | 40.0 | 40.0 | 63.6 | 57.1 | 42.9 | 45.8 |
ACR50 represents at least 50% improvement from Baseline in TJC (68 joints) + in SJC (66 joints) + in at least 3 of 5 core set measures: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), total score (0-3) computed from item scores, with lower scores meaning less disability. • CRP in mg/L. Missing values were considered as non-responding status.
| Percentage of responders | RA0083 CDP6038 (Olokizumab) 120 mg q2w | RA0083 CDP6038 (Olokizumab) 120 mg q4w | RA0083 CDP6038 (Olokizumab) 240 mg q4w | RA0083 CDP6038 (Olokizumab) 60 mg q2w | RA0083 CDP6038 (Olokizumab) 60 mg q4w | RA0083 Placebo |
|---|---|---|---|---|---|---|
| The ACR50 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0083) at Week 48 of Study RA0089 | 20.0 | 13.3 | 45.5 | 14.3 | 17.9 | 29.2 |
ACR50:atleast 50% improvement from Baseline in TJC (68 joints) + in SJC (66 joints) + in at least 3 of 5 core set measures: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), total score (0-3) computed from item scores, with lower scores meaning less disability. • CRP in mg/L. Missing values were considered as non-responding status. Since the study was terminated early before Week 96, no data was collected and analyzed at the Week 96 and this Outcome Measure has zero total participants analyzed.
Results for this outcome have not been posted.
ACR70 represents at least 70% improvement from Baseline in TJC (68 joints) + in SJC (66 joints) + in at least 3 of 5 core set measures: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), total score (0-3) computed from item scores, with lower scores meaning less disability. • CRP in mg/L. Missing values were considered as non-responding status.
| Percentage of responders | RA0083 CDP6038 (Olokizumab) 120 mg q2w | RA0083 CDP6038 (Olokizumab) 120 mg q4w | RA0083 CDP6038 (Olokizumab) 240 mg q4w | RA0083 CDP6038 (Olokizumab) 60 mg q2w | RA0083 CDP6038 (Olokizumab) 60 mg q4w | RA0083 Placebo |
|---|---|---|---|---|---|---|
| The ACR 70% (ACR70) Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0083) at Week 12 of Study RA0089 | 30.0 | 26.7 | 27.3 | 21.4 | 17.9 | 29.2 |
ACR70 represents at least 70% improvement from Baseline in TJC (68 joints) + in SJC (66 joints) + in at least 3 of 5 core set measures: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), total score (0-3) computed from item scores, with lower scores meaning less disability. • CRP in mg/L. Missing values were considered as non-responding status.
| Percentage of responders | RA0083 CDP6038 (Olokizumab) 120 mg q2w | RA0083 CDP6038 (Olokizumab) 120 mg q4w | RA0083 CDP6038 (Olokizumab) 240 mg q4w | RA0083 CDP6038 (Olokizumab) 60 mg q2w | RA0083 CDP6038 (Olokizumab) 60 mg q4w | RA0083 Placebo |
|---|---|---|---|---|---|---|
| The ACR70 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0083) at Week 24 of Study RA0089 | 10.0 | 20.0 | 54.5 | 42.9 | 32.1 | 25.0 |
ACR70 represents at least 70% improvement from Baseline in TJC (68 joints) + in SJC (66 joints) + in at least 3 of 5 core set measures: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), total score (0-3) computed from item scores, with lower scores meaning less disability. • CRP in mg/L. Missing values were considered as non-responding status.
| Percentage of responders | RA0083 CDP6038 (Olokizumab) 120 mg q2w | RA0083 CDP6038 (Olokizumab) 120 mg q4w | RA0083 CDP6038 (Olokizumab) 240 mg q4w | RA0083 CDP6038 (Olokizumab) 60 mg q2w | RA0083 CDP6038 (Olokizumab) 60 mg q4w | RA0083 Placebo |
|---|---|---|---|---|---|---|
| The ACR70 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0083) at Week 48 of Study RA0089 | 10.0 | 13.3 | 18.2 | 14.3 | 7.1 | 16.7 |
ACR70:atleast 70% improvement from Baseline in TJC (68 joints) + in SJC (66 joints) + in at least 3 of 5 core set measures: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), total score (0-3) computed from item scores, with lower scores meaning less disability. • CRP in mg/L. Missing values were considered as non-responding status. Since the study was terminated early before Week 96, no data was collected and analyzed at the Week 96 and this Outcome Measure has zero total participants analyzed.
Results for this outcome have not been posted.
DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, andCRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included shoulders, elbows, wrists; MCP, thumb IP, and PIP joints of hands; and knees. Scores on DAS28(CRP) range from 0 to approximately 10, where scores \>5.1 correspond with active disease, scores \<3.2 correspond with well controlled disease, and scores \<2.6 correspond with remission or similar. Percentage of participants with DAS28(CRP) \<2.6 were reported.
| Percentage of subjects | RA0083 CDP6038 (Olokizumab) 120 mg q2w | RA0083 CDP6038 (Olokizumab) 120 mg q4w | RA0083 CDP6038 (Olokizumab) 240 mg q4w | RA0083 CDP6038 (Olokizumab) 60 mg q2w | RA0083 CDP6038 (Olokizumab) 60 mg q4w | RA0083 Placebo |
|---|---|---|---|---|---|---|
| Percentage of Subjects With DAS28(CRP) <2.6 at Week 12 of Study RA0089 | 50.00 | 64.29 | 70.00 | 53.85 | 43.48 | 39.13 |
DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, andCRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included shoulders, elbows, wrists; MCP, thumb IP, and PIP joints of hands; and knees. Scores on DAS28(CRP) range from 0 to approximately 10, where scores \>5.1 correspond with active disease, scores \<3.2 correspond with well controlled disease, and scores \<2.6 correspond with remission or similar. Percentage of participants with DAS28(CRP) \<2.6 were reported.
| Percentage of subjects | RA0083 CDP6038 (Olokizumab) 120 mg q2w | RA0083 CDP6038 (Olokizumab) 120 mg q4w | RA0083 CDP6038 (Olokizumab) 240 mg q4w | RA0083 CDP6038 (Olokizumab) 60 mg q2w | RA0083 CDP6038 (Olokizumab) 60 mg q4w | RA0083 Placebo |
|---|---|---|---|---|---|---|
| Percentage of Subjects With DAS28(CRP) <2.6 at Week 24 of Study RA0089 | 50.00 | 77.78 | 80.00 | 54.55 | 59.09 | 40.91 |
DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, andCRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included shoulders, elbows, wrists; MCP, thumb IP, and PIP joints of hands; and knees. Scores on DAS28(CRP) range from 0 to approximately 10, where scores \>5.1 correspond with active disease, scores \<3.2 correspond with well controlled disease, and scores \<2.6 correspond with remission or similar. Percentage of participants with DAS28(CRP) \<2.6 were reported.
| Percentage of subjects | RA0083 CDP6038 (Olokizumab) 120 mg q2w | RA0083 CDP6038 (Olokizumab) 120 mg q4w | RA0083 CDP6038 (Olokizumab) 240 mg q4w | RA0083 CDP6038 (Olokizumab) 60 mg q2w | RA0083 CDP6038 (Olokizumab) 60 mg q4w | RA0083 Placebo |
|---|---|---|---|---|---|---|
| Percentage of Subjects With DAS28(CRP) <2.6 at Week 48 of Study RA0089 | 66.67 | 100.00 | 83.33 | 100.00 | 42.86 | 55.56 |
DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, andCRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included shoulders, elbows, wrists; MCP, thumb IP, and PIP joints of hands; and knees. Scores on DAS28(CRP) range from 0 to approximately 10, where scores \>5.1 correspond with active disease, scores \<3.2 correspond with well controlled disease, and scores \<2.6 correspond with remission or similar. Percentage of participants with DAS28(CRP) \<2.6 were reported. Since the study was terminated early before Week 96, no data was collected and analyzed at the Week 96 and this Outcome Measure has zero total participants analyzed.
Results for this outcome have not been posted.
DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, andCRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included shoulders, elbows, wrists; MCP, thumb IP, and PIP joints of hands; and knees. Scores on DAS28(CRP) range from 0 to approximately 10, where scores \>5.1 correspond with active disease, scores \<3.2 correspond with well controlled disease, and scores \<2.6 correspond with remission or similar. Percentage of participants with DAS28(CRP) less than or equal to (≤) 3.2 were reported.
| Percentage of subjects | RA0083 CDP6038 (Olokizumab) 120 mg q2w | RA0083 CDP6038 (Olokizumab) 120 mg q4w | RA0083 CDP6038 (Olokizumab) 240 mg q4w | RA0083 CDP6038 (Olokizumab) 60 mg q2w | RA0083 CDP6038 (Olokizumab) 60 mg q4w | RA0083 Placebo |
|---|---|---|---|---|---|---|
| Percentage of Subjects With DAS28(CRP) ≤3.2 at Week 12 of Study RA0089 | 100.00 | 71.43 | 80.00 | 69.23 | 78.26 | 65.22 |
DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, andCRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included shoulders, elbows, wrists; MCP, thumb IP, and PIP joints of hands; and knees. Scores on DAS28(CRP) range from 0 to approximately 10, where scores \>5.1 correspond with active disease, scores \<3.2 correspond with well controlled disease, and scores \<2.6 correspond with remission or similar. Percentage of participants with DAS28(CRP) ≤3.2 were reported.
| Percentage of subjects | RA0083 CDP6038 (Olokizumab) 120 mg q2w | RA0083 CDP6038 (Olokizumab) 120 mg q4w | RA0083 CDP6038 (Olokizumab) 240 mg q4w | RA0083 CDP6038 (Olokizumab) 60 mg q2w | RA0083 CDP6038 (Olokizumab) 60 mg q4w | RA0083 Placebo |
|---|---|---|---|---|---|---|
| Percentage of Subjects With DAS28(CRP) ≤3.2 at Week 24 of Study RA0089 | 87.50 | 100.00 | 90.00 | 81.82 | 72.73 | 77.27 |
DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, andCRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included shoulders, elbows, wrists; MCP, thumb IP, and PIP joints of hands; and knees. Scores on DAS28(CRP) range from 0 to approximately 10, where scores \>5.1 correspond with active disease, scores \<3.2 correspond with well controlled disease, and scores \<2.6 correspond with remission or similar. Percentage of participants with DAS28(CRP) ≤3.2 were reported.
| Percentage of subjects | RA0083 CDP6038 (Olokizumab) 120 mg q2w | RA0083 CDP6038 (Olokizumab) 120 mg q4w | RA0083 CDP6038 (Olokizumab) 240 mg q4w | RA0083 CDP6038 (Olokizumab) 60 mg q2w | RA0083 CDP6038 (Olokizumab) 60 mg q4w | RA0083 Placebo |
|---|---|---|---|---|---|---|
| Percentage of Subjects With DAS28(CRP) ≤3.2 at Week 48 of Study RA0089 | 66.67 | 100.00 | 100.00 | 100.00 | 71.43 | 77.78 |
DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, andCRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included shoulders, elbows, wrists; MCP, thumb IP, and PIP joints of hands; and knees. Scores on DAS28(CRP) range from 0 to approximately 10, where scores \>5.1 correspond with active disease, scores \<3.2 correspond with well controlled disease, and scores \<2.6 correspond with remission or similar. Since the study was terminated early before Week 96, no data was collected and analyzed at the Week 96 and this Outcome Measure has zero total participants analyzed.
Results for this outcome have not been posted.
CDAI was calculated using the TJC (28 joints), SJC (28 joints), PtGADA-VAS and PhGADA-VAS, according to the following formula: SJC + TJC + PtGADA + PhGADA Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 10 cm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • PhGADA: 10 cm VAS (0=very good, asymptomatic and no limitation of normal activities; 100=very poor, very severe symptoms which were intolerable and inability to carry out all normal activities). The 28 joints included the shoulders, elbows, wrists; MCP, thumb IP, and PIP joints of the hands; and the knees. Total score range is from 0-100, with the high scores representing high disease activity. A negative change in CDAI score indicates an improvement in disease activity.
| units on a scale | RA0083 CDP6038 (Olokizumab) 120 mg q2w | RA0083 CDP6038 (Olokizumab) 120 mg q4w | RA0083 CDP6038 (Olokizumab) 240 mg q4w | RA0083 CDP6038 (Olokizumab) 60 mg q2w | RA0083 CDP6038 (Olokizumab) 60 mg q4w | RA0083 Placebo |
|---|---|---|---|---|---|---|
| Change From Baseline (Week 0 of Study RA0083) in the Clinical Disease Activity Index (CDAI) at Week 48 of Study RA0089 | -72.0000 ± 86.13362 | -108.0256 ± 77.85787 | -95.1667 ± 24.41652 | -75.2870 ± 46.83603 | -94.7363 ± 54.63562 | -99.9744 ± 41.83169 |
CDAI was calculated using the TJC (28 joints), SJC (28 joints), PtGADA-VAS and PhGADA-VAS, according to the following formula: SJC + TJC + PtGADA + PhGADA Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 10 cm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • PhGADA: 10 cm VAS (0=very good, asymptomatic and no limitation of normal activities; 100=very poor, very severe symptoms which were intolerable and inability to carry out all normal activities). The 28 joints included the shoulders, elbows, wrists; MCP, thumb IP, and PIP joints of the hands; and the knees. Total score range is from 0-100, with the high scores representing high disease activity. A negative change in CDAI score indicates an improvement in disease activity. Since the study was terminated early before Week 96, no data was collected and analyzed at the Week 96 and this Outcome Measure has zero total participants analyzed.
Results for this outcome have not been posted.
SDAI was calculated using the TJC (28 joints), SJC (28 joints), PtGADA-VAS, PhGADA-VAS and CRP (mg/dL\]), according to the following formula: SJC + TJC + PtGADA + PhGADA + CRP (mg/dL) Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 10 cm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • PhGADA: 10 cm VAS (0=very good, asymptomatic and no limitation of normal activities; 100=very poor, very severe symptoms which were intolerable and inability to carry out all normal activities). • CRP range was from 0 to 10 mg/dL. The 28 joints included the shoulders, elbows, wrists; MCP, thumb IP, and PIP joints of the hands; and the knees. The SDAI score ranges from 0 to 86, with higher scores representing worse disease. A negative change in SDAI score indicates an improvement in disease activity.
| units on a scale | RA0083 CDP6038 (Olokizumab) 120 mg q2w | RA0083 CDP6038 (Olokizumab) 120 mg q4w | RA0083 CDP6038 (Olokizumab) 240 mg q4w | RA0083 CDP6038 (Olokizumab) 60 mg q2w | RA0083 CDP6038 (Olokizumab) 60 mg q4w | RA0083 Placebo |
|---|---|---|---|---|---|---|
| Change From Baseline (Week 0 of Study RA0083) in the Simplified Disease Activity Index (SDAI) at Week 48 of Study RA0089 | -75.6667 ± 90.23488 | -130.6923 ± 97.08073 | -125.1667 ± 48.85659 | -93.7870 ± 61.23550 | -113.3077 ± 53.87161 | -127.8633 ± 38.49694 |
SDAI was calculated using the TJC (28 joints), SJC (28 joints), PtGADA-VAS, PhGADA-VAS and CRP (mg/dL\]), as per formula: SJC + TJC + PtGADA + PhGADA + CRP (mg/dL) Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 10 cm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • PhGADA: 10 cm VAS (0=very good, asymptomatic and no limitation of normal activities; 100=very poor, very severe symptoms which were intolerable and inability to carry out all normal activities). • CRP range was from 0 to 10 mg/dL. The 28 joints included the shoulders, elbows, wrists; MCP, thumb IP, and PIP joints of the hands; and the knees. SDAI score ranges from 0 to 86, with higher scores representing worse disease. A negative change in SDAI score indicates an improvement in disease activity. Since the study was terminated early before Week 96, no data was collected and analyzed at the Week 96 and this Outcome Measure has zero total participants analyzed.
Results for this outcome have not been posted.
The CDP6038 (olokizumab) plasma levels data were not collected and analyzed. This Outcome Measure therefore has zero total participants analyzed.
Results for this outcome have not been posted.
The CDP6038 (olokizumab) plasma levels data were not collected and analyzed. This Outcome Measure therefore has zero total participants analyzed.
Results for this outcome have not been posted.
Collected over From Baseline (Week 0 of Study RA0089) until 30 days after the last dose (maximum up to 562 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| RA0083 CDP6038 (Olokizumab) 120 mg q2w | 0/10 (0%) | 1/10 (10%) | 8/10 (80%) |
| RA0083 CDP6038 (Olokizumab) 120 mg q4w | 0/15 (0%) | 0/15 (0%) | 13/15 (86.7%) |
| RA0083 CDP6038 (Olokizumab) 240 mg q4w | 0/11 (0%) | 2/11 (18.2%) | 10/11 (90.9%) |
| RA0083 CDP6038 (Olokizumab) 60 mg q2w | 0/15 (0%) | 2/15 (13.3%) | 12/15 (80%) |
| RA0083 CDP6038 (Olokizumab) 60 mg q4w | 0/28 (0%) | 5/28 (17.9%) | 25/28 (89.3%) |
| RA0083 Placebo | 0/24 (0%) | 4/24 (16.7%) | 21/24 (87.5%) |
| Event | RA0083 CDP6038 (Olokizumab) 120 mg q2w | RA0083 CDP6038 (Olokizumab) 120 mg q4w | RA0083 CDP6038 (Olokizumab) 240 mg q4w | RA0083 CDP6038 (Olokizumab) 60 mg q2w | RA0083 CDP6038 (Olokizumab) 60 mg q4w | RA0083 Placebo |
|---|---|---|---|---|---|---|
| HaemorrhoidsGastrointestinal disorders | 1/10 | 0/15 | 0/11 | 0/15 | 0/28 | 0/24 |
| Subdural haematomaInjury, poisoning and procedural complications | 1/10 | 0/15 | 0/11 | 0/15 | 0/28 | 0/24 |
| Duodenal ulcer haemorrhageGastrointestinal disorders | 0/10 | 0/15 | 1/11 | 0/15 | 0/28 | 0/24 |
| Non-Hodgkin's lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/10 | 0/15 | 1/11 | 0/15 | 0/28 | 0/24 |
| GastroenteritisInfections and infestations | 0/10 | 0/15 | 0/11 | 1/15 | 0/28 | 0/24 |
| PneumoniaInfections and infestations | 0/10 | 0/15 | 0/11 | 1/15 | 0/28 | 0/24 |
| PleurisyRespiratory, thoracic and mediastinal disorders | 0/10 | 0/15 | 0/11 | 1/15 | 0/28 | 0/24 |
| CellulitisInfections and infestations | 0/10 | 0/15 | 0/11 | 0/15 | 1/28 | 1/24 |
| EpiglottitisInfections and infestations | 0/10 | 0/15 | 0/11 | 0/15 | 0/28 | 1/24 |
| Femoral neck fractureInjury, poisoning and procedural complications | 0/10 | 0/15 | 0/11 | 0/15 | 0/28 | 1/24 |
| Event | RA0083 CDP6038 (Olokizumab) 120 mg q2w | RA0083 CDP6038 (Olokizumab) 120 mg q4w | RA0083 CDP6038 (Olokizumab) 240 mg q4w | RA0083 CDP6038 (Olokizumab) 60 mg q2w | RA0083 CDP6038 (Olokizumab) 60 mg q4w | RA0083 Placebo |
|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 3/10 | 6/15 | 2/11 | 6/15 | 9/28 | 8/24 |
| StomatitisGastrointestinal disorders | 3/10 | 2/15 | 3/11 | 1/15 | 2/28 | 2/24 |
| GastroenteritisInfections and infestations | 0/10 | 1/15 | 3/11 | 2/15 | 1/28 | 0/24 |
| PharyngitisInfections and infestations | 0/10 | 1/15 | 3/11 | 1/15 | 0/28 | 0/24 |
| Alanine aminotransferase increasedInvestigations | 0/10 | 0/15 | 1/11 | 1/15 | 0/28 | 5/24 |
| Aspartate aminotransferase increasedInvestigations | 0/10 | 0/15 | 0/11 | 1/15 | 0/28 | 5/24 |
| Injection site erythemaGeneral disorders | 2/10 | 2/15 | 1/11 | 0/15 | 2/28 | 2/24 |
| Injection site indurationGeneral disorders | 2/10 | 0/15 | 0/11 | 0/15 | 0/28 | 0/24 |
| Seasonal allergyImmune system disorders | 2/10 | 0/15 | 0/11 | 1/15 | 1/28 | 1/24 |
| Herpes zosterInfections and infestations | 0/10 | 3/15 | 1/11 | 2/15 | 0/28 | 1/24 |
Safety Population included all enrolled subjects who received at least 1 injection of CDP6038 (olokizumab) in Study RA0089.
| Age, Categorical(Participants) | RA0083 CDP6038 (Olokizumab) 120 mg q2w | RA0083 CDP6038 (Olokizumab) 120 mg q4w | RA0083 CDP6038 (Olokizumab) 240 mg q4w | RA0083 CDP6038 (Olokizumab) 60 mg q2w | RA0083 CDP6038 (Olokizumab) 60 mg q4w | RA0083 Placebo | Total |
|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 7 | 11 | 10 | 13 | 23 | 18 | 82 |
| >=65 years | 3 | 4 | 1 | 2 | 5 | 6 | 21 |
| Sex: Female, Male(Participants) | RA0083 CDP6038 (Olokizumab) 120 mg q2w | RA0083 CDP6038 (Olokizumab) 120 mg q4w | RA0083 CDP6038 (Olokizumab) 240 mg q4w | RA0083 CDP6038 (Olokizumab) 60 mg q2w | RA0083 CDP6038 (Olokizumab) 60 mg q4w | RA0083 Placebo | Total |
|---|---|---|---|---|---|---|---|
| Female | 7 | 12 | 9 | 12 | 27 | 21 | 88 |
| Male | 3 | 3 | 2 | 3 | 1 | 3 | 15 |
Ran from Jan 2012 to primary completion in Nov 2013, 22 months.
Results were first posted in May 2022, 8 years 5 months after primary completion. A results delay was requested in Aug 2014.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Olokizumab